Compare Johnson & Johnson (JNJ) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Sunrun Inc — how do they compare? Johnson & Johnson trades at $250.04 (market cap $598.96B), while Sunrun Inc trades at $11.66 (market cap $2.73B). The key difference: Johnson & Johnson is far larger — about 219.4× Sunrun Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| JNJ | RUN | |
|---|---|---|
Market Cap | $598.96B | $2.73B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $21.41 |
52-Week Low | $164.36 | $9.07 |
Enterprise Value | $631.90B | $16.92B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Sunrun (RUN) trades at $11.44, down 3.46% today, with a bearish technical outlook. The stock shows strong profitability with a 17.88% net income margin and trades at a low P/E of 5.56. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, boosting growth prospects. Earnings have consistently beaten estimates, with Q1 2026 EPS of $0.62 versus -$0.05 expected.
The outlook is mixed: analyst consensus is bullish with a $16.27 price target, but cash flow concerns and high debt-to-asset ratio of 70.76% pose risks. The partnership with Tesla offers significant upside in the AI-driven energy demand sector, yet execution and financing challenges remain key hurdles for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
